Vice President, Development Asset Leader, Liver Franchise

The role

The Development Asset Leader will lead in vivo LNP-delivered liver programs from early clinical development through licensure. This role involves owning the Integrated Development Plan and leading a matrixed team to advance multiple clinical assets.

What you will do

• Own the Integrated Development Plan for liver assets from IND acceptance through regulatory approval/licensure
• Anticipate, frame, and escalate critical considerations that change the asset's risk/value profile to executive management
• Lead a matrixed team spanning Clinical, Regulatory, CMC/Manufacturing, Biostatistics, Pharmacovigilance, Med Affairs/Patient Advocacy, and Commercial
• Deploy AI-enabled project management tooling
• Help design team structure, governance cadence, and knowledge-transfer processes as the liver franchise expands
• Serve as a key point of contact with CROs/CDMOs, KOLs, and patient advocacy groups
• Represent the asset in regulatory interactions alongside Regulatory Affairs

Required qualifications

• 12+ years of drug development experience in biotech/pharma
• Demonstrated leadership of a clinical-stage asset from IND through late-stage development
• Track record of cross-functional program leadership and accountability spanning Clinical, Regulatory, CMC, and Nonclinical
• Demonstrated ability to influence without formal authority, build team culture, and manage external partners

Nice to have

• Advanced degree in life sciences, medicine, or related field (PhD, MD, PharmD)
• Direct experience in genetic medicines (gene/gene editing therapies, RNA-based therapeutics)
• Rare disease experience
• Liver-directed or LNP delivery experience
• Experience or genuine interest in applying AI tools to project/portfolio management
• Comfort operating in a lean, resource-constrained organization

Benefits

• Medical
• Dental
• Vision
• Life insurance
• 401(k) match
• Equity programs
• Generous paid time off
• Wellness days
• Company-wide recharge breaks

About the company

Prime Medicine is a clinical-stage biotechnology company pioneering Prime Editing, a novel and precise gene editing technology. The company is advancing a broad pipeline of Prime Editing–based therapies to develop curative genetic therapies.